Stratec annual meeting approves dividend, shares anchored in German healthcare segment
23.06.2026 - 18:28:02 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 18:26.
Stratec (DE000STRA555) held its latest annual general meeting recently, where shareholders approved a dividend and all proposed resolutions, according to an EQS release carried by Deutsche Börse. The diagnostics specialist remains listed in the Prime Standard segment in Frankfurt alongside peers such as Siemens Healthineers in the European healthcare space.
What the AGM decided
According to the EQS news summary on FinanzNachrichten, the Stratec annual general meeting approved the distribution of a cash dividend and backed all management and supervisory board proposals on the agenda. The meeting also confirmed the company’s status in the Prime Standard of the Frankfurt Stock Exchange, keeping it within the German healthcare and medtech peer group.
The EQS dispatch emphasizes that shareholders supported every resolution, indicating broad backing for the board’s course. With the AGM decisions, Stratec continues its practice of paying a dividend from its diagnostics equipment business, a field where larger peers like Siemens Healthineers and Roche also operate in Europe.
Tuesday focus on analyst views
On a Tuesday, analyst and consensus views provide an important reference point for Stratec in the absence of intraday trading data on Xetra, where the Deutsche Börse page currently shows a last price indication of 0 euros with no turnover for the day. The listing details confirm the ticker STRA55 and the ISIN DE000STRA555 in the Prime Standard segment of the Frankfurt market.
While there is no fresh broker report dated today in the German data aggregators, Stratec is typically covered in the medtech and diagnostics niche by regional houses such as Berenberg or Warburg alongside larger healthcare players like Siemens Healthineers and bioMérieux, according to prior consensus overviews on German financial portals. For investors, these analyst assessments frame expectations around margins and growth in automated laboratory systems.
All news and analysis on the Stratec shares
Further reports, company releases and price data on Stratec can be found in the dedicated topic area and on the group’s investor-relations site.
The diagnostics business model
Stratec develops and manufactures automated analyzer systems and integrated software for in-vitro diagnostics companies, operating mainly as an original equipment manufacturer for large diagnostics brands. Its systems are used in medical laboratories for applications such as immunoassays and molecular diagnostics, where reliability and throughput are central to customer demand.
Where the stock trades today
The Stratec shares (DE000STRA555) are listed in Frankfurt under the ticker STRA55 in the Prime Standard; the live Deutsche Börse page on Xetra showed a technical last price indication of 0.00 euros with no current trading turnover at the latest update.
Key data on the Stratec shares
- Company: STRATEC SE
- ISIN: DE000STRA555
- WKN: STRA55
- Ticker: STRA55
- Trading venue: Frankfurt / Xetra (Prime Standard)
- Price (as of latest Xetra indication): 0.00 EUR
- Market cap: not disclosed in the latest Deutsche Börse indication
- Sector / industry: Healthcare, medical technology / diagnostics
- Index membership: Prime Standard (no major selection index reported)
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, an offer, or a recommendation to buy or sell securities. Investors should conduct their own research and, where appropriate, consult a licensed financial advisor before making investment decisions.
